PE20220563A1 - Conjugados peptidicos de citotoxinas como terapeuticos - Google Patents

Conjugados peptidicos de citotoxinas como terapeuticos

Info

Publication number
PE20220563A1
PE20220563A1 PE2022000039A PE2022000039A PE20220563A1 PE 20220563 A1 PE20220563 A1 PE 20220563A1 PE 2022000039 A PE2022000039 A PE 2022000039A PE 2022000039 A PE2022000039 A PE 2022000039A PE 20220563 A1 PE20220563 A1 PE 20220563A1
Authority
PE
Peru
Prior art keywords
cytotoxins
topoisomerase
peptide conjugates
therapeutics
diseases
Prior art date
Application number
PE2022000039A
Other languages
English (en)
Inventor
Daniel Richard Marshall
Johanna Marie Csengery
Robert John Maguire
Robert A Volkmann
Original Assignee
Cybrexa 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 2 Inc filed Critical Cybrexa 2 Inc
Publication of PE20220563A1 publication Critical patent/PE20220563A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invencion se refiere a conjugados peptidicos de citotoxinas tales como inhibidores de topoisomerasa I que son utiles para el tratamiento de enfermedades tal como cancer. Se proporciona un compuesto de Formula (I): R8 - Q - R7, o una sal farmaceuticamente aceptable del mismo, en donde: R7 es un peptido; R8 es una porcion dirigida a topoisomerasa I de molecula pequena, que se une a la topoisomerasa I; y Q es un enlazador, que se enlaza covalentemente a la porcion R7 y R8. Tambien se refiere al uso de estos compuestos en el tratamiento de enfermedades que involucran tejido enfermo acido o hipoxico, tales como cancer o enfermedades neurodegenerativas.
PE2022000039A 2019-07-10 2020-07-09 Conjugados peptidicos de citotoxinas como terapeuticos PE20220563A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872643P 2019-07-10 2019-07-10
US202063040859P 2020-06-18 2020-06-18
PCT/US2020/041411 WO2021007435A1 (en) 2019-07-10 2020-07-09 Peptide conjugates of cytotoxins as therapeutics

Publications (1)

Publication Number Publication Date
PE20220563A1 true PE20220563A1 (es) 2022-04-13

Family

ID=71787212

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000039A PE20220563A1 (es) 2019-07-10 2020-07-09 Conjugados peptidicos de citotoxinas como terapeuticos

Country Status (17)

Country Link
US (2) US11634508B2 (es)
EP (1) EP3997093A1 (es)
JP (1) JP2022541749A (es)
KR (1) KR20220052918A (es)
CN (1) CN114341162A (es)
AU (1) AU2020309570A1 (es)
BR (1) BR112022000337A2 (es)
CA (1) CA3146560A1 (es)
CL (1) CL2022000038A1 (es)
CO (1) CO2022001316A2 (es)
CR (1) CR20220058A (es)
EC (1) ECSP22010228A (es)
IL (1) IL289658A (es)
MX (1) MX2022000449A (es)
PE (1) PE20220563A1 (es)
TW (1) TW202116778A (es)
WO (1) WO2021007435A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
IL301793A (en) 2020-09-30 2023-05-01 Duality Biologics Suzhou Co Ltd Anticancer compound and method for its preparation and use
EP4274905A1 (en) 2021-01-08 2023-11-15 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
CA3218253A1 (en) 2021-04-29 2022-11-03 Cybrexa 2, Inc. Dosing regimens of peptide conjugates of topoisomerase i inhibitors
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
WO2023091957A1 (en) * 2021-11-17 2023-05-25 Cybrexa 4, Inc. Peptide conjugates of peptidic tubulin inhibitors as therapeutics
TW202342025A (zh) * 2022-03-18 2023-11-01 大陸商映恩生物製藥（蘇州）有限公司 Gpc3抗體藥物偶聯物及其用途
WO2023191209A1 (ko) * 2022-03-29 2023-10-05 주식회사 퓨전바이오텍 친수성 펩타이드를 포함하는 마이셀 및 이의 용도

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
BR9610051A (pt) 1995-08-02 1999-12-21 Univ Newcastle Ventures Ltd Uso de um composto, processo de preparação do mesmo, formulação ou composição farmacêutica contendo um composto, composição farmacêutica, e, processo de tratamento terapeutico
DE69707860T2 (de) 1996-04-26 2002-04-11 Daiichi Seiyaku Co Verfahren zur herstellung von tetrahydroindolizinen
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
IN189180B (es) 1997-07-09 2003-01-04 Chong Kun Dang Corp
CA2333321A1 (en) 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Drug complex
MXPA01004239A (es) 1998-10-30 2002-06-04 Daiichi Seiyaku Co Compuesto dds y metodo para la medicion del mismo.
ID28787A (id) 1998-11-03 2001-07-05 Basf Ag 2-fenilbenzimidazol tersubstitusi, pembuatannya dan penggunaannya
AU781711B2 (en) 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
WO2001041534A2 (en) 1999-12-13 2001-06-14 Eli Lilly And Company Pseudomycin phosphate prodrugs
BR0112417A (pt) 2000-07-13 2003-07-01 Daiichi Seiyaku Co Composições farmacêuticas contendo composto dds
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1487493B1 (en) 2002-03-01 2010-01-20 The Administrators of The Tulane Educational Fund Conjugates of cytotoxic agents and biologically active peptides
IL164022A0 (en) 2002-03-20 2005-12-18 Bristol Myers Squibb Co Phosphate derivatives of fluoroxindole and pharmaceutical compositions containing the same
CA2482806A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2520997A1 (en) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
CA2930485C (en) 2003-05-14 2018-04-10 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP3031810B1 (en) 2003-05-20 2019-03-06 ImmunoGen, Inc. Maytansinoid-cell-binding agent conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
DE602004025123D1 (en) 2003-07-25 2010-03-04 Pfizer Tricyclische parp-hemmer
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
NZ547984A (en) 2003-12-01 2009-03-31 Kudos Pharm Ltd DNA damage repair inhibitors for treatment of cancer
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
MX2007003314A (es) 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
KR100876520B1 (ko) 2004-09-22 2008-12-31 화이자 인코포레이티드 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법
AU2005286191B2 (en) 2004-09-22 2011-11-17 Cancer Research Technology Ltd. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
DK1819359T3 (en) 2004-12-09 2015-04-20 Janssen Biotech Inc ANTI-integrin immunoconjugates, processes for their preparation and their use
EP1846014B1 (en) 2005-01-18 2012-10-24 The Board of Governors for Higher Education State of Rhode Island and Providence Plantations Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally sensitive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
KR20070120156A (ko) 2005-04-15 2007-12-21 이뮤노젠 아이엔씨 종양에서 이종 또는 혼성 세포 집단의 제거 방법
EP1928503B1 (en) 2005-08-24 2012-10-03 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
CN101316834A (zh) 2005-09-29 2008-12-03 艾博特公司 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
PL1945647T3 (pl) 2005-11-08 2012-04-30 Immunogen Inc Procesy wytwarzania maytansinolu
EP2329818A1 (en) 2006-01-17 2011-06-08 Abbott Laboratories Combination therapy with PARP inhibitors
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
RS51780B (en) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. INDASOLS SUBSTITUTED BY AMIDE AS INHIBITORS OF POLY (ADP-Ribose) POLYMERASES (PARP)
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
AU2008268432B2 (en) * 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
EP3831380A3 (en) 2007-08-17 2021-12-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
CA2722109A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Potent conjugates and hydrophilic linkers
PT2437790T (pt) 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
US9353140B2 (en) 2009-11-25 2016-05-31 Academia Sinica BQC-G, a tumor-selective anti-cancer prodrug
ES2753748T3 (es) 2010-02-12 2020-04-14 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
WO2011106639A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2752422B1 (en) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
EP4321168A2 (en) 2010-07-13 2024-02-14 Yale University, Inc. Environmentally sensitive compositions
EP2603201B1 (en) 2010-08-13 2020-03-11 Rhode Island Board of Governors for Higher Education Liposome compositions and methods of use thereof
BR112013010853A2 (pt) 2010-11-03 2016-08-16 Immunogen Inc "agentes citotóxicos compreendendo derivados de ansamitocina, composição farmacêutica e uso destes"
TR201902180T4 (tr) 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
MX350152B (es) 2011-10-14 2017-08-29 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CN104755494B (zh) 2012-10-11 2018-09-07 第一三共株式会社 抗体－药物偶联物
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
EP2911701A4 (en) 2012-10-23 2016-06-08 Univ Johns Hopkins Novel self-assembling drug amphiphiles and methods for synthesis and application
WO2014093343A2 (en) 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
AU2014369019B2 (en) 2013-12-19 2020-09-17 Seagen Inc. Methylene carbamate linkers for use with targeted-drug conjugates
WO2015108986A1 (en) 2014-01-16 2015-07-23 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
LT3129063T (lt) 2014-04-10 2021-06-25 Daiichi Sankyo Company, Limited Anti-her3 antikūno-vaisto konjugatas
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
EP3110447B1 (en) 2014-09-16 2020-04-29 Synermore Biologics Co., Ltd. Anti-egfr antibody and uses of same
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
LT3380486T (lt) 2015-11-24 2020-05-11 Theravance Biopharma R&D Ip, Llc Jak inhibitoriaus junginio provaistai, skirti virškinimo trakto uždegiminės ligos gydymui
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
US20200078468A1 (en) 2016-04-13 2020-03-12 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
US20190133980A1 (en) 2016-06-02 2019-05-09 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
CA3032401A1 (en) 2016-07-29 2018-02-01 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
MX2019001905A (es) 2016-08-16 2019-05-15 Aist Peptido objetivo de tumor maligno.
WO2018057912A1 (en) 2016-09-22 2018-03-29 Rhode Island Council On Postsecondary Education FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A pH -TRIGGERED POLYPEPTIDE
EP3634498A4 (en) 2017-06-09 2021-08-25 Rhode Island Council on Postsecondary Education CONNECTED AND OTHER PH-RIGIDED CONNECTIONS
KR102422860B1 (ko) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
WO2019136298A1 (en) 2018-01-05 2019-07-11 Cybrexa, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
KR20200109345A (ko) 2018-01-12 2020-09-22 프로린크스 엘엘시 상승적 암 치료
HRP20230787T1 (hr) 2018-05-18 2023-10-27 Glycotope Gmbh Anti-muc1 antitijelo
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
US20200237926A1 (en) 2019-01-28 2020-07-30 Rhode Island Council On Postsecondary Education pHLIP® targeted delivery of potent cytotoxic compounds
US20220211863A1 (en) 2019-03-29 2022-07-07 Medimmune Limited Compounds and conjugates thereof
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.

Also Published As

Publication number Publication date
US20210009719A1 (en) 2021-01-14
US20240010755A1 (en) 2024-01-11
WO2021007435A1 (en) 2021-01-14
EP3997093A1 (en) 2022-05-18
CO2022001316A2 (es) 2022-05-10
CR20220058A (es) 2022-07-19
TW202116778A (zh) 2021-05-01
AU2020309570A1 (en) 2022-02-03
CN114341162A (zh) 2022-04-12
CA3146560A1 (en) 2021-01-14
MX2022000449A (es) 2022-04-25
CL2022000038A1 (es) 2022-08-19
BR112022000337A2 (pt) 2022-04-12
JP2022541749A (ja) 2022-09-27
US11634508B2 (en) 2023-04-25
ECSP22010228A (es) 2022-05-31
KR20220052918A (ko) 2022-04-28
IL289658A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
PE20220563A1 (es) Conjugados peptidicos de citotoxinas como terapeuticos
BR112022010383A2 (pt) Compostos tricíclicos substituídos
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
CY1120088T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου ως φαρμακo
PE20181953A1 (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
CY1119942T1 (el) Μεθοδοι θεραπειας της ψωριασης χρησιμοποιωντας ανταγωνιστες της il-17
IN2014CN04961A (es)
UY31800A (es) Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CR20130534A (es) Nuevos derivados de imidazol útiles para el tratamiento de artritis
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
BR112012029405A8 (pt) compostos macrocíclicos como inibidores de trk quinase
EA201692530A1 (ru) Цитотоксические пептиды и их конъюгаты
CR10567A (es) Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap)
SV2004001393A (es) Benzamida, heteroarilamida y amidas inversas ref. pc23106
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
PE20191660A1 (es) Dendrimeros terapeuticos
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
EA201291246A1 (ru) Конденсированные бициклические ингибиторы киназы
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CO2022001315A2 (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos